HK1219021A1 - 以類轉錄活化因子核酸酶為基礎的基因修正 - Google Patents

以類轉錄活化因子核酸酶為基礎的基因修正

Info

Publication number
HK1219021A1
HK1219021A1 HK16107060.2A HK16107060A HK1219021A1 HK 1219021 A1 HK1219021 A1 HK 1219021A1 HK 16107060 A HK16107060 A HK 16107060A HK 1219021 A1 HK1219021 A1 HK 1219021A1
Authority
HK
Hong Kong
Prior art keywords
talen
based gene
gene correction
correction
gene
Prior art date
Application number
HK16107060.2A
Other languages
English (en)
Inventor
Mark J Osborn
Jakub Tolar
Bruce Blazar
Daniel F Voytas
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of HK1219021A1 publication Critical patent/HK1219021A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
HK16107060.2A 2013-03-01 2016-06-20 以類轉錄活化因子核酸酶為基礎的基因修正 HK1219021A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361771735P 2013-03-01 2013-03-01
PCT/US2014/019322 WO2014134412A1 (en) 2013-03-01 2014-02-28 Talen-based gene correction

Publications (1)

Publication Number Publication Date
HK1219021A1 true HK1219021A1 (zh) 2017-03-24

Family

ID=51428832

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107060.2A HK1219021A1 (zh) 2013-03-01 2016-06-20 以類轉錄活化因子核酸酶為基礎的基因修正

Country Status (8)

Country Link
US (4) US9393257B2 (zh)
EP (2) EP3567104A1 (zh)
JP (3) JP6480874B2 (zh)
AU (2) AU2014223243B2 (zh)
CA (1) CA2902954A1 (zh)
ES (1) ES2750550T3 (zh)
HK (1) HK1219021A1 (zh)
WO (1) WO2014134412A1 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850497B2 (en) * 2013-11-04 2017-12-26 Regents Of The University Of Minnesota Gene targeting methods and tools
KR20220100078A (ko) 2014-01-31 2022-07-14 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
MX2017006408A (es) 2014-11-17 2018-03-23 Adicet Bio Inc Linfocitos t gamma delta modificados geneticamente.
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN104726495B (zh) * 2015-03-25 2018-06-19 西北农林科技大学 一种基于talen介导的基因打靶敲除山羊blg的载体及重组细胞
EP3277805A1 (en) 2015-03-31 2018-02-07 Exeligen Scientific, Inc. Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism
CN108026566A (zh) 2015-05-04 2018-05-11 特拉维夫大学拉莫特有限公司 用于使dna片段化的方法和试剂盒
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
IL295616A (en) 2015-07-31 2022-10-01 Us Health Adapted cells and treatment methods
US20180296600A1 (en) * 2015-10-27 2018-10-18 The Board Of Trustees Of The Leland Stanford Junior University Treatment of epidermolysis bullosa by injection of autologous collagen vii overexpressing leukocytes
PL3377637T3 (pl) 2016-04-08 2020-09-07 Krystal Biotech, Inc. Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
WO2017197347A1 (en) 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール2 セラピューティクス インク. 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
WO2018075664A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN110234343A (zh) 2016-12-21 2019-09-13 T细胞受体治疗公司 用于治疗癌症的经工程改造t细胞
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
US20190365929A1 (en) * 2017-02-22 2019-12-05 Crispr Therapeutics Ag Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
EP3638776A1 (en) 2017-06-14 2020-04-22 Technische Universität Dresden Methods and means for genetic alteration of genomes utilizing designer dna recombining enzymes
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
AU2018370120B2 (en) 2017-11-15 2023-11-09 Adicet Therapeutics, Inc. Methods for selective expansion of d3 yd T-cell populations and compositions thereof
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
KR20210005141A (ko) 2018-04-27 2021-01-13 크리스탈 바이오테크, 인크. 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산
EP4252759A3 (en) 2018-05-11 2023-11-08 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
CA3102975A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
WO2020068862A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
EP3887395A4 (en) 2018-11-30 2022-07-27 Intima Bioscience, Inc. METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES
BR112021010804A2 (pt) 2018-12-03 2021-11-16 Adicet Bio Inc Métodos para expansão seletiva in vivo de populações de células t gama delta e composições das mesmas
AU2020219343A1 (en) 2019-02-08 2021-08-19 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
WO2020257684A1 (en) 2019-06-20 2020-12-24 University Of Massachusetts Compositions and methods for improved gene editing
EP3999627A2 (en) 2019-07-18 2022-05-25 University of Rochester Cell-type selective immunoprotection of cells
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
GB2605276A (en) 2019-09-03 2022-09-28 Myeloid Therapeutics Inc Methods and compositions for genomic integration
WO2022051418A1 (en) 2020-09-01 2022-03-10 64-X, Inc. Mammalian cells and methods for engineering the same
KR20230088833A (ko) 2020-10-23 2023-06-20 루트패스 제노믹스, 인크. T-세포 수용체 식별을 위한 조성물 및 방법
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
US11753677B2 (en) 2021-11-10 2023-09-12 Encodia, Inc. Methods for barcoding macromolecules in individual cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161817A1 (en) 2001-06-04 2004-08-19 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
SG181601A1 (en) 2009-12-10 2012-07-30 Univ Minnesota Tal effector-mediated dna modification
WO2012033462A1 (en) * 2010-09-06 2012-03-15 Temasek Life Sciences Laboratory Limited Molecular interaction between xa10 and avrxa10
JP6336755B2 (ja) * 2010-11-12 2018-06-06 ザ ジェネラル ホスピタル コーポレイション ポリコームに関連する非コードrna
CN103917644A (zh) * 2011-09-21 2014-07-09 桑格摩生物科学股份有限公司 调控转基因表达的方法和组合物

Also Published As

Publication number Publication date
JP6480874B2 (ja) 2019-03-13
EP2961262B1 (en) 2019-07-24
JP2019089821A (ja) 2019-06-13
EP2961262A4 (en) 2016-10-12
CA2902954A1 (en) 2014-09-04
US20210187006A1 (en) 2021-06-24
US20140256798A1 (en) 2014-09-11
US10973844B2 (en) 2021-04-13
EP3567104A1 (en) 2019-11-13
US20160367588A1 (en) 2016-12-22
EP2961262A1 (en) 2016-01-06
US9393257B2 (en) 2016-07-19
AU2020200307A1 (en) 2020-02-06
AU2014223243A1 (en) 2015-09-10
NZ711254A (en) 2021-02-26
WO2014134412A1 (en) 2014-09-04
JP2021088565A (ja) 2021-06-10
JP2016512960A (ja) 2016-05-12
ES2750550T3 (es) 2020-03-26
JP6893945B2 (ja) 2021-06-23
US20190054111A1 (en) 2019-02-21
US10172880B2 (en) 2019-01-08
AU2014223243B2 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
HK1219021A1 (zh) 以類轉錄活化因子核酸酶為基礎的基因修正
HRP20182063T1 (hr) Gen otpornosti na rizomaniju
GB201413149D0 (en) No details
FI2956477T4 (fi) Optimoitu tekijä viii:n geeni
GB201410903D0 (en) No details
RS64292B1 (sr) Fotobioreaktor
IL242777A (en) Building system elements
GB201408089D0 (en) No details
GB201416327D0 (en) No details
GB201305997D0 (en) Cathode
GB201407200D0 (en) No details
GB201414328D0 (en) None
GB201417843D0 (en) No details
HK1216152A1 (zh) 複合體
GB201410951D0 (en) None
GB201309132D0 (en) Regulatable gene expression
GB201318949D0 (en) Genes
GB201303157D0 (en) Refractive correction
GB201410424D0 (en) None
GB201323055D0 (en) No details
GB201323056D0 (en) No details
GB201323054D0 (en) No details
GB201307978D0 (en) No details
HU4268U (en) Multi purposal glass-panel